Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
26.4.2022 15:45:00 EEST | Business Wire | Press release
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion’s proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic melanoma.
“We believe we have found the key to efficiently activating the immune system to combat cancer. With our core AI tool called PIONEER, we accurately predict the patient’s most potent neoepitopes, which are the significant mutations of cancer. Then we train the immune system to target those exact mutations, not everything else. That means a higher precision in the therapy than the standard of care treatments out there,” said Lars Wegner, CEO of Evaxion. “We are happy to work with Personalis on this crucial next step when we embark on the Phase 2b study, potentially bringing us closer to fulfilling our aspiration of saving the lives of patients with our AI-powered immunotherapy.”
“Over the past decade, a number of drugs have emerged based on the discovery that the immune system plays a key role in fighting cancer. However, the development of new therapies has been challenged by difficulties in understanding the precise interaction between cancer and the immune system,” said John West, CEO and co-founder of Personalis. “ImmunoID NeXT provides a broad set of insights on tumor and immune biology. Our collaboration with Evaxion may contribute to a better understanding of how combination therapeutics can improve patient outcomes and offer the path to companion diagnostics when relevant biomarkers are identified.”
ImmunoID NeXT® provides a comprehensive, multidimensional view of both a tumor and its immune microenvironment from a single sample. The platform consolidates multiple biomarker assays into one, including advanced analysis of mechanisms of tumor escape, human leukocyte antigen typing and loss of heterozygosity, microsatellite instability, gene expression signatures, T-cell and B-cell receptor repertoires, and immunocellular quantification. ImmunoID NeXT offers a seamless platform for discovery, from translational testing to companion diagnostics.
About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates, which currently includes three patient-specific cancer immunotherapies.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, expected benefits of Personalis’ collaboration with Evaxion, Personalis’ business opportunities, leadership, plans or expectations, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, the company’s registration statement on Form S-3 filed on December 30, 2020, and the company’s prospectus supplement filed on January 3, 2022, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005194/en/
Contact information
Media Contact for Evaxion:
Katrine Hertz Mortensen
khm@evaxion-biotech.com
www.evaxion-biotech.com
+45 3010 0203
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Temple
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sparxity Closes Series A, Bringing Total Funding to $90M10.11.2026 15:00:00 EET | Press release
Sparxity, a leader in sparse-native computing, today announced the close of its Series A, bringing cumulative funding secured by its team to $90M. The round was led by ICM HPQC Fund and joined by investors such as Lockheed Martin Ventures, GlobalFoundries, GS Futures, Cloudberry Ventures, TGFS and the EIC Fund. The financing also includes angel investments from TIME100 AI leaders Richard Socher (Recursive Superintelligence) and Nancy Xu (Salesforce-acquired Moonhub), alongside continued support from Atlantic and Silicon Catalyst. The funding will accelerate the development of specialized chips for fine-grained dynamic sparsity, targeting up to 44× faster AI inference in ultra-sparse models, bringing greater energy efficiency by computing only what matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110433588/en/ The Sparxity Multi-Rack System “Our work with PEER demonstrated the potential of dynamic sparsity, activati
Transition Industries Selects Technip Energies as PMC Partner for Pacifico Mexinol Ultra-Low Carbon Methanol Project10.11.2026 15:00:00 EET | Press release
Transition Industries announces the selection of Technip Energies as its Project Management Consultancy (PMC) partner for the Pacifico Mexinol project, located in Sinaloa, Mexico, which is expected to become the world's largest ultra-low carbon chemical production facility. Once operational, the facility will produce annually approximately 350,000 metric tons of RFNBO (Renewable Fuel of Non-Biological Origin) methanol and 1.8 million metric tons of ultra-low carbon methanol from natural gas with carbon capture, helping meet growing global demand through a lower-carbon production model. “We are pleased that Technip Energies has joined the project team and will bring their global project management expertise to our landmark industrial development project in Mexico. Technip Energies was selected for their project management expertise, technical know-how and execution capabilities,” says Diego Martinez, Transition Industries Chief Operating Officer. The project will use existing infrastruc
Telia Estonia trials Adtran 50G PON technology to prepare for next-generation broadband services10.11.2026 15:00:00 EET | Press release
Adtran today announced that Telia Estonia, part of Nordic and Baltic telecommunications operator Telia Company, is trialing its 50G PON technology as the next step in the evolution of its fiber broadband infrastructure. Building on its deployment of Adtran’s fiber access platform, the proof of concept (PoC) will evaluate how 50G PON can coexist with existing GPON and XGS-PON services on a common network infrastructure. The trial will help Telia Estonia prepare for future residential and business connectivity requirements while providing a practical framework for introducing higher-capacity services as market needs develop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110315607/en/ Adtran’s 50G PON technology is helping Telia Estonia prepare for the rollout of next-generation digital services. “Today, we cannot yet accurately predict which services we’ll be using in ten or twenty years’ time. What we can already see, how
Nebul Adopts NetApp Novus to Power Sovereign AI Infrastructure10.11.2026 15:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that Nebul, a European AI-native cloud provider, is the first neocloud to adopt NetApp Novus™, its new high-performance architecture designed to deliver the fastest storage on the planet. Nebul is building the Intelligent Cloud, a sovereign platform integrating accelerated infrastructure, enterprise data services and production AI capabilities. Novus, now generally available, is designed to maximize utilization for millions of GPUs and is architected for up to 100 TB per second of aggregate throughput. Moving quickly to adopt the groundbreaking technology, Nebul and NetApp are exploring new opportunities to help organizations achieve AI-powered advantage and unlock greater value from their data. Bringing together Nebul’s sovereign AI services and the proven power of the NetApp Platform, the companies are exploring opportunities to accelerate the adoption of sovereign AI while giving enterprises the sec
Vasion ® Fall Release Eliminates Dark Documents and Makes Operational Documents AI Ready10.11.2026 15:00:00 EET | Press release
Vasion, the Intelligent Document Automation company, announced its fall release, which captures the context behind operational documents and makes them ready for AI without IT giving up control. Vasion will demonstrate it at Microsoft Ignite, November 17-21, in San Francisco, booth 5509. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110362305/en/ Vasion® Fall Release Eliminates Dark Documents and Makes Operational Documents AI Ready “Every company runs on operational documents: the invoices, claims, contracts, and intake forms that move money and make decisions,” said Scott Lee, Chief Product Officer at Vasion. “But the moment one of those documents is printed or scanned, it loses the context that explains it, so the AI a company invests in can’t see the work its people actually do. This release captures that context where the document is born and gives IT the control to put it to work.” Operational documents are what wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom